Figure 1

MLPA profiles for control individuals (red), and for the HSCR patients (blue). For these HSCR cases, an increase in the dosage of EDN3 exon 4 (a) and RET exon 17 (b) can be observed.
MLPA profiles for control individuals (red), and for the HSCR patients (blue). For these HSCR cases, an increase in the dosage of EDN3 exon 4 (a) and RET exon 17 (b) can be observed.